Oragenics (NYSEAMERICAN:OGEN) Shares Up 1.4% – Here’s What Happened

Oragenics, Inc. (NYSEAMERICAN:OGEN) shares traded up 1.4% during mid-day trading on Wednesday . The company traded as high as $0.5329 and last traded at $0.5061. Approximately 25,336 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 36,526 shares. The stock had previously closed at $0.4990.

Oragenics Price Performance

The company’s 50-day simple moving average is $0.54 and its two-hundred day simple moving average is $0.62. The firm has a market capitalization of $2.28 million, a P/E ratio of -0.02 and a beta of 1.25.

Oragenics (NYSEAMERICAN:OGEN) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.57) EPS for the quarter.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in OGEN. XTX Topco Ltd purchased a new stake in Oragenics in the 4th quarter worth approximately $26,000. Bank of America Corp DE raised its stake in Oragenics by 7,374.0% during the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after acquiring an additional 15,338 shares during the period. Finally, DRW Securities LLC lifted its holdings in Oragenics by 82.4% during the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock valued at $88,000 after purchasing an additional 50,900 shares in the last quarter. 18.71% of the stock is owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.